|本期目录/Table of Contents|

[1]吴佳佳,王艺茹,张子豪,等.基于网络药理学和非靶向代谢组学研究栀子治疗高尿酸血症的作用机制[J].天津医科大学学报,2026,32(03):247-255.[doi:10.20135/j.issn.1006-8147.2026.03.0247]
　WU Jiajia,WANG Yiru,ZHANG Zihao,et al.Investigation of the therapeutic mechanisms of Gardenia jasminoides in hyperuricemia based on network pharmacology and untargeted metabolomics[J].Journal of Tianjin Medical University,2026,32(03):247-255.[doi:10.20135/j.issn.1006-8147.2026.03.0247]
点击复制

基于网络药理学和非靶向代谢组学研究栀子治疗高尿酸血症的作用机制(PDF)

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
32卷
期数:
2026年03期
页码:
247-255
栏目:
基础医学
出版日期:
2026-05-20

文章信息/Info

Title:
Investigation of the therapeutic mechanisms of Gardenia jasminoides in hyperuricemia based on network pharmacology and untargeted metabolomics
文章编号:
1006-8147（2026）03-0247-09
作者:
吴佳佳1; 王艺茹1; 张子豪1; 刘惠娟1; 2; 李荣珊1
1.天津医科大学药学院，天津300070;2.甘肃医学院药学院，平凉744000
Author(s):
WU Jiajia1; WANG Yiru1; ZHANG Zihao1; LIU Huijuan1; 2; LI Rongshan1
1.School of Pharmacy， Tianjin Medical University， Tianjin 300070， China;2.School of Pharmacy， Gansu Medical College， Pingliang 744000， China
关键词:
栀子; 高尿酸血症; 非靶向代谢组学; 网络药理学
Keywords:
Gardenia jasminoides;  hyperuricemia;  untargeted metabolomics;  network pharmacology
分类号:
R9
DOI:
10.20135/j.issn.1006-8147.2026.03.0247
文献标志码:
A
摘要:
目的：整合网络药理学及代谢组学技术，系统阐释栀子提取物治疗高尿酸血症（HUA）的作用机制。方法：基于网络药理学确定栀子中的活性化合物及其潜在治疗靶点，构建蛋白质-蛋白质相互作用（PPI）网络，进行基因功能（GO）和京都基因与基因组百科全书（KEGG）通路富集分析，以推测关键的信号通路。将30只大鼠随机分为5组，分别为空白组（CON）、模型组（MOD）、GJ提取物高（GJH）、低（GJL）剂量组和别嘌醇（AP）组，每组6只。采用高酵母饲料联合氧嗪酸钾诱导大鼠HUA，测定治疗前后血清尿酸水平，干预后血清肌酐（Cr）、尿素氮（BUN）和肝脏黄嘌呤氧化酶（XOD）水平。超高效液相色谱-质谱法鉴别差异代谢产物分析相关代谢通路。结果：在栀子提取物中共获得17个活性化合物和15个关键靶点，主要干预磷脂酰肌醇3激酶-蛋白激酶B（PI3K-Akt）、Janus激酶-信号转导与转录激活因子（JAK-STAT）等多条信号通路。与MOD组相比，给药组大鼠血清尿酸水平显著降低（F=28.93，P<0.001），Cr（F=12.79，P<0.001）、BUN（F=90.47，P<0.001）和XOD（F=62.23，P<0.001）水平明显改善。非靶向代谢组学鉴定出149个差异代谢物，51个可被显著回调，涉及磷酸戊糖途径、嘌呤代谢及组氨酸代谢等；整合分析确认黄嘌呤脱氢酶（XDH）为栀子提取物抗HUA的核心作用靶点。结论：栀子提取物通过多靶点、多通路治疗HUA。
Abstract:
Objective： To systematically elucidate the mechanism of Gardenia jasminoides extract in treating hyperuricemia（HUA） by integrating network pharmacology and metabolomics. Methods： Active compounds and potential therapeutic targets of Gardenia jasminoides were identified based on network pharmacology. Protein-protein interaction（PPI） network was constructed， followed by the Gene Ontology（GO） and Kyoto Encyclopedia of Genes and Genomes（KEGG） pathway enrichment analyses to predict key sig-naling pathways. Thirty rats were randomly divided into five groups： the control group（CON）， model group（MOD）， high-dose（GJH） and low-dose（GJL） Gardenia jasminoides extract groups， and allopurinol group（AP）， with 6 rats in each group. HUA was induced in rats by high-yeast diet combined with potassium oxonate. Serum uric acid levels were measured before and after treatment， while serum creatinine（Cr）， blood urea nitrogen（BUN）， and hepatic xanthine oxidase（XOD） levels were determined after intervention. Differential metabolites were identified using ultra-high performance liquid chromatography-mass spectrometry（UPLC-MS）， and re-lated metabolic pathways were analyzed. Results： A total of 17 active compounds and 15 key targets were obtained from Gardenia jasminoides extract， mainly intervening in phosphatidylinositol 3 kinase-protein kinase B（PI3K-Akt）， Janus kinase/signal transduc-er and activator of transcription（JAK-STAT）， and other signaling pathways. Compared with the model group， the serum uric acid lev-els in the treatment groups were significantly decreased（F=28.93， P<0.001）， with marked improvements in Cr（F=12.79， P<0.001）， BUN（F=90.47， P<0.001）， and XOD（F=62.23， P<0.001） levels. Untargeted metabolomics identified 149 differential meta-bolites， of which 51 were significantly reversed by Gardenia jasminoides extract， involving the pentose phosphate pathway， purine metabolism， and histidine metabolism. Integrated analysis confirmed xanthine dehydrogenase（XDH） as the core target of Gardenia jasminoides extract against HUA. Conclusion： Gardenia jasminoides extract treats HUA through multiple targets and pathways.

参考文献/References:

[1] FU Y， LUO X D， LI J Z， et al. Host-derived Lactobacillus plan-tarum alleviates hyperuricemia by improving gut microbial commu-nity and hydrolase-mediated degradation of purinenucleosides [J]. Elife， 2024，13：e100068.
[2] BARNINI C， RUSSO E， LEONCINI G， et al. Asymptomatic hyper-uricemia and the kidny：lessons from the URRAH study[J]. Meta-bolites， 2025，15（1）3：11.
[3] GUO J， LIU H， JIN T， et al. Moslae Herba extract alleviates hyper-uricemia by regulatinguric acid metabolism and relieving renal in-flammation and fibrosis in mice[J]. Phytomedicine， 2025， 145：156974.
[4] SUN Z， ZHANG X， ZHAO Z，et al. Recent progress and future per-spectives on anti-hyperuricemic agents[J]. J Med Chem， 2024，67 （22）：19966-19987.
[5] CHEN L， LI M， YANG Z， et al. Gardenia jasminoides Ellis：ethnopharmacology， phytochemistry， and pharmacological and in-dustrial applications of an important traditional Chinese medicine[J]. J Ethnopharmacol， 2020，257：112829.
[6] ZHANG Q， LIANG J， LI X， et al. Exploring antithrombotic mecha-nisms and effective constituents of Lagopsis supina using an inte-grated strategy based on network pharmacology，molecular docking， metabolomics， and experimental verification in rats[J]. J Ethnophar-macol， 2025，336：118717.
[7] MAO Y， XU H， XIA P. Ilex cornuta leaves extracts ameliorate hy-peruricemia by modulatinguric acid transporters[J]. J Ethnopharma-col， 2025，336：118618.
[8] LIAO Y， WANG M， QIN F， et al. Integrating network pharmacolo-gy， quantitative transcripomic analysis， and experimental valida-tion revealed the mechanism of cordycepin in the treatment of obe-sity[J]. Front Pharmacol， 2025，16：1571480.
[9] JIAO L， WANG R， DONG Y， et al. The impact of chrysanthemi in-dici flos-enriched flavonoidpart on the model of hyperuricemia based on inhibiting synthesis and promoting excretionof uric acid[J]. J Ethnopharmacol， 2024，333：118488.
[10] QIN Y， ZHANG X， TAO H， et al. Ameliorative effect and mecha-nism of Yi-Suan-Cha againsthyperuricemia in rats[J]. J Clin Lab Anal， 2021，35（8）：e23859.
[11] LIANG S， XU D， WU J， et al. Phyllanthi fructus ameliorates hype-ruricemia and kidney injure via inhibiting uric acid synthesis， modulating urate transporters， and alleviating inflammation[J]. Sci Rep， 2024，14（1）：27605.
[12] WANG Y， YU Z， ZHANG Z， et al. Integrating metabolomics with network pharmacology to reveal the mechanism of Poria cocos in hy-peruricemia treatment [J]. J Ethnopharmacol， 2025，337（Pt 3）：118977.
[13] CHEN J S， WANG M X， WANG M M， et al. Synthesis and biologi-cal evaluation of geniposide derivatives as inhibitors of hyperurice-mia， inflammatory and fibrosis[J]. Eur J Med Chem， 2022， 237：114379.
[14] DU L， ZONG Y， LI H， et al. Hyperuricemia and its related dis-eases： mechanisms and advances in therapy[J]. Signal Transduct Target Ther. 2024，9（1）：212.
[15] YE J， YAO J， XU S， et al. Elucidating the substance basis and pharmacological mechanismof Fufang Qiling granules in modulating xanthine oxidase for intervention in hyperuricemia[J]. J Ethnophar-macol， 2024，333：118410.
[16] TOYODA Y， TAKADA T， SAITO H， et al. Identification of inhi-bitory activities of dietary flavonoids against URAT1， a renal urate reabsorber： in vitro screening and fractional approach focused on rooibos leaves[J]. Nutrients， 2022，14（3）：575.
[17] HU Y Y， LIU X， XIA Q， et al. Comparative anti-arthritic investi-gation of iridoid glycosides and crocetin derivatives from Gardenia jasminoides Ellis in Freund′s complete adjuvantinduced arthritis in rats[J]. Phytomedicine， 2019，53：223-233.
[18] SUN H L， BIAN H G， LIU X M， et al. GRP/GRPR signaling path-way aggravates hyperuricemia-induced renal inflammation and fi-brosis via ABCG2-dependent mechanisms[J]. Biochem Pharmacol， 2023，218：115901.
[19] WANG J， ZHANG Y， ZHOU M，et al. Rapid screening and evalua-tion of XOD inhibitors and O（2）（*-） scavenger from total flavonoids of Ginkgo biloba leaves by LC-MS and multimode mi-croplate reader[J]. Biomed Chromatogr， 2020，34（8）：e4852.
[20] ZHANG Z， WANG P， LEI T， et al. The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout[J]. Front Pharmacol， 2025，16：1480844.
[21] LIN G， YU Q， XU L， et al. Berberrubine attenuates potassium ox-onate and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathwy[J]. Eur J Pharma-col， 2021，912：174592.
[22] TIAN J， XU Y， XIONG Y， et al. Metabolomics combined with net-work pharmacology to explore the mechanisms of modified Guishen pill to ameliorate polycystic ovary syndrome[J]. Comput Biol Med， 2022，148：105790.
[23] MAIUOLO J， OPPEDISANO F， GRATTERI S， et al. Regulation of uric acid metabolism and excretion[J]. Int J Cardiol， 2016， 213： 8-14.
[24] TIAN J， XU Y， XIONG Y， et al. Metabolomics combined with net-work pharmacology to explore the mechanisms of modified Guishen pill to ameliorate polycystic ovary syndrome[J]. Comput Biol Med， 2022， 148： 105790.

相似文献/References:

[1]苏东峰,聂秀玲,孙丽荣.2型糖尿病合并高尿酸血症临床特征及相关危险因素分析[J].天津医科大学学报,2013,19(06):481.
[2]郭彩云,聂秀玲,孙丽荣,等.高尿酸血症/痛风与非酒精性脂肪肝严重程度的相关研究[J].天津医科大学学报,2013,19(06):499.
　GUO Cai-yun,NIE Xiu-ling,SUN Li-rong,et al.Hyperuricemia or gout associated with the severity of nonalcoholic fatty liver disease[J].Journal of Tianjin Medical University,2013,19(03):499.
[3]连宇航,余胡燕,田志霞,等.高尿酸血症对特发性膜性肾病患者肾小管萎缩/间质纤维化的预测价值[J].天津医科大学学报,2022,28(04):403.
　LIAN Yu-Hang,YU Hu-Yan,TIAN Zhi-Xia,et al.Predictive value of hyperuricemia on tubular atrophy/interstitial fibrosis in patients with idiopathic membranous nephropathy[J].Journal of Tianjin Medical University,2022,28(03):403.
[4]王玉华,张 峰,王亚林,等.基于网络药理学及分子对接探讨栀子治疗良性前列腺增生症的作用机制[J].天津医科大学学报,2026,32(02):153.[doi:10.20135/j.issn.1006-8147.2026.02.0153]
　WANG Yuhua,ZHANG Feng,WANG Yalin,et al.Exploring the mechanism of Gardeniae Fructus in the treatment of benign prostatic hyperplasia based on network pharmacology and molecular docking[J].Journal of Tianjin Medical University,2026,32(03):153.[doi:10.20135/j.issn.1006-8147.2026.02.0153]

备注/Memo

备注/Memo:
作者简介 吴佳佳（1997-），女，硕士在读，研究方向：药学；通信作者：李荣珊，E-mail：lirongshan@tmu.edu.cn；刘惠娟，E-mail：liuhuijuan722@163.com。
（2025-10-24收稿）
更新日期/Last Update: 2026-05-25